Skip to main content
Top
Gepubliceerd in: Tijdschrift voor Urologie 6/2011

01-10-2011 | Noodzaak tot zelfkatheterisatie na intravesicale botulinetoxine-A-injecties

Noodzaak tot zelfkatheterisatie na intravesicale botulinetoxine-A-injecties

Auteurs: F.T. Jansen, K.P.J. Delaere

Gepubliceerd in: Tijdschrift voor Urologie | Uitgave 6/2011

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Intravesicale botulinetoxine-A-injecties bij patiënten met incontinentie ten gevolge van detrusoroveractiviteit, is een relatief nieuwe behandeling met een goed tijdelijk resultaat. Er werd onderzoek gedaan naar het risico op postmictioneel residu en dus was er na iedere injectie afhankelijkheid van een katheter. Het risico op significante urineretentie is na 4 injecties gemiddeld 22% en lijkt niet te veranderen met het toenemen van het aantal injecties. Van alle patiënten die zelfkatheterisatie (clean intermittent catheterization, CIC) toepassen zal twee derde blijvend afhankelijk worden van CIC.
Literatuur
1.
go back to reference Schurch B, Stohrer M, Kramer G, et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164:692–697.PubMedCrossRef Schurch B, Stohrer M, Kramer G, et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164:692–697.PubMedCrossRef
2.
go back to reference Karsenty G, Reitz, A, Lindemann G, et al. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology. 2006;68:1193–1197.PubMedCrossRef Karsenty G, Reitz, A, Lindemann G, et al. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology. 2006;68:1193–1197.PubMedCrossRef
3.
go back to reference Patki PS, Hamid R, Arumugam K, et al. Botulinum toxin-type A in the treatment of drug-resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury. BJU Int. 2006;98:77–82.PubMedCrossRef Patki PS, Hamid R, Arumugam K, et al. Botulinum toxin-type A in the treatment of drug-resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury. BJU Int. 2006;98:77–82.PubMedCrossRef
4.
go back to reference Schurch B, de Seze M, Denys P, et al. Botulinum toxin is a safe and effective treatment for neurogenic urinary incontinence: results from a single-treatment randomized placebo controlled 6 month study. J Urol. 2005;174:196–200.PubMedCrossRef Schurch B, de Seze M, Denys P, et al. Botulinum toxin is a safe and effective treatment for neurogenic urinary incontinence: results from a single-treatment randomized placebo controlled 6 month study. J Urol. 2005;174:196–200.PubMedCrossRef
5.
go back to reference Ghei M, Maraj BH, Miller R, et al. Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol. 2005;174:1873–1877.PubMedCrossRef Ghei M, Maraj BH, Miller R, et al. Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol. 2005;174:1873–1877.PubMedCrossRef
6.
go back to reference Reitz A, Denys P, Fermanian C, et al. Do Repeat Intradetrusor Botulinum Toxin Type A Injection Yield Valuable Results? Clinical and Urodynamic Results after Fiver Injections in Patients with Neurogenic Detrusor Overactivity. Eur Urol. 2007;52:1729–1735.PubMedCrossRef Reitz A, Denys P, Fermanian C, et al. Do Repeat Intradetrusor Botulinum Toxin Type A Injection Yield Valuable Results? Clinical and Urodynamic Results after Fiver Injections in Patients with Neurogenic Detrusor Overactivity. Eur Urol. 2007;52:1729–1735.PubMedCrossRef
7.
go back to reference Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single centre, randomized, double-blind, placebo controlled trial. J Urol. 2007;177:2231–2236.PubMedCrossRef Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single centre, randomized, double-blind, placebo controlled trial. J Urol. 2007;177:2231–2236.PubMedCrossRef
8.
go back to reference Grosse J, Kramer G, Stöhrer M. Success of Repeat Detrusor Injections of Botulinum A Toxin in Patients with Severe Neurogenic Detrusor Overactivity and Incontinence. Eur Urol. 2005;47:653–659.PubMedCrossRef Grosse J, Kramer G, Stöhrer M. Success of Repeat Detrusor Injections of Botulinum A Toxin in Patients with Severe Neurogenic Detrusor Overactivity and Incontinence. Eur Urol. 2005;47:653–659.PubMedCrossRef
9.
go back to reference Popat R, Apostolidis A, Kalsi V, et al. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol. 2005;174:984–989.PubMedCrossRef Popat R, Apostolidis A, Kalsi V, et al. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol. 2005;174:984–989.PubMedCrossRef
10.
go back to reference Kalsi V, Gonzales G, Popat R, et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol. 2007;62:452–457PubMedCrossRef Kalsi V, Gonzales G, Popat R, et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol. 2007;62:452–457PubMedCrossRef
11.
go back to reference Martinek J, Siroky M, Plottova Z, et al. Treatment of patients with achalasia with botulinum toxin: a multicenter prospective cohort study. Dis Esophagus. 2003; 16:204–209.PubMedCrossRef Martinek J, Siroky M, Plottova Z, et al. Treatment of patients with achalasia with botulinum toxin: a multicenter prospective cohort study. Dis Esophagus. 2003; 16:204–209.PubMedCrossRef
12.
go back to reference Brubaker L, Richter HE, Visco A, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol. 2008;180:217–222.PubMedCrossRef Brubaker L, Richter HE, Visco A, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol. 2008;180:217–222.PubMedCrossRef
13.
go back to reference Kalsi V, Apostolidis A, Popat R, et al. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol. 2006;49:528–535.PubMedCrossRef Kalsi V, Apostolidis A, Popat R, et al. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol. 2006;49:528–535.PubMedCrossRef
14.
go back to reference Khan S, Kessler TM, Apostolidis A, et al. What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection. The Journal of urology. 2009;181:1773–1778.PubMedCrossRef Khan S, Kessler TM, Apostolidis A, et al. What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection. The Journal of urology. 2009;181:1773–1778.PubMedCrossRef
15.
go back to reference Sahai A, Dowson C, Khan MS, et al. Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity. Urology. 2010;75:552–558.PubMedCrossRef Sahai A, Dowson C, Khan MS, et al. Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity. Urology. 2010;75:552–558.PubMedCrossRef
16.
go back to reference Sahai A, Sangster P, Kalsi V, et al. Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable? BJU Int. 2009;103:630–634.PubMedCrossRef Sahai A, Sangster P, Kalsi V, et al. Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable? BJU Int. 2009;103:630–634.PubMedCrossRef
17.
go back to reference Schmid MD, Sauermann P, Werner M, et al. Experience with 100 cases treated with botulinum-a toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. The Journal of urology. 2006;176:177–185.PubMedCrossRef Schmid MD, Sauermann P, Werner M, et al. Experience with 100 cases treated with botulinum-a toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. The Journal of urology. 2006;176:177–185.PubMedCrossRef
18.
go back to reference Schulte-Baukloh H, Knispel HH, Stolze T, et al. Repeated botulinum-A toxin injections in treatment of children with neurogenic detrusor overactivity. Urology. 2005;66:865–870.PubMedCrossRef Schulte-Baukloh H, Knispel HH, Stolze T, et al. Repeated botulinum-A toxin injections in treatment of children with neurogenic detrusor overactivity. Urology. 2005;66:865–870.PubMedCrossRef
19.
go back to reference Kuo HC. Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? Urol. 2006;68:993–997.PubMedCrossRef Kuo HC. Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? Urol. 2006;68:993–997.PubMedCrossRef
20.
go back to reference Karsenty G, Boy S, Reitz, et al. Botulinum toxin A (BTA) in the treatment of neurogenic detrusor overactivity incontinence (NDOI): a prospective randomized study to compare 30 vs 10 injection sites [abstract 93]. Neururol Urodyn. 2005;24:547–548. Karsenty G, Boy S, Reitz, et al. Botulinum toxin A (BTA) in the treatment of neurogenic detrusor overactivity incontinence (NDOI): a prospective randomized study to compare 30 vs 10 injection sites [abstract 93]. Neururol Urodyn. 2005;24:547–548.
21.
go back to reference Kuo HC. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J Urol. 2007;178:1359–1363.PubMedCrossRef Kuo HC. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J Urol. 2007;178:1359–1363.PubMedCrossRef
22.
go back to reference Smith CP, Chancellor MB. Simplified bladder botulinum-toxin delivery technique using flexible cystoscope and 10 sites of injection. J Endourol. 2005;19:880–882.PubMedCrossRef Smith CP, Chancellor MB. Simplified bladder botulinum-toxin delivery technique using flexible cystoscope and 10 sites of injection. J Endourol. 2005;19:880–882.PubMedCrossRef
23.
go back to reference Kessler TM, Ryu G, Burkhard FC. Clean intermittent selfcatheterization: A burden for the patient? Neurourol Urodyn. 2009;28:18–21.PubMedCrossRef Kessler TM, Ryu G, Burkhard FC. Clean intermittent selfcatheterization: A burden for the patient? Neurourol Urodyn. 2009;28:18–21.PubMedCrossRef
24.
go back to reference Kessler TM, Khan S, Panicker J, et al. Clean intermittent Self-Catheterization After Botulinum Neurotoxin Type A Injections. Obstet Gynecol. 2009;113:1046–1051.PubMed Kessler TM, Khan S, Panicker J, et al. Clean intermittent Self-Catheterization After Botulinum Neurotoxin Type A Injections. Obstet Gynecol. 2009;113:1046–1051.PubMed
Metagegevens
Titel
Noodzaak tot zelfkatheterisatie na intravesicale botulinetoxine-A-injecties
Auteurs
F.T. Jansen
K.P.J. Delaere
Publicatiedatum
01-10-2011
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Tijdschrift voor Urologie / Uitgave 6/2011
Print ISSN: 2211-3037
Elektronisch ISSN: 2211-4718
DOI
https://doi.org/10.1007/s13629-011-0060-3

Andere artikelen Uitgave 6/2011

Tijdschrift voor Urologie 6/2011 Naar de uitgave

Mictiegerelateerde zwelling van het scrotum

Mictiegerelateerde zwelling van het scrotum: een casus

Een ulcus op de penis als eerste manifestatie van morbus Wegener

Een ulcus op de penis als eerste manifestatie van morbus Wegener

Editorial

Editorial

Sentinel-nodebiopsie bij peniscarcinoom na eerdere primaire tumorbehandeling

Sentinel-nodebiopsie voor stadiëring van de lies bij peniscarcinoom na eerdere primaire tumorbehandeling